In his lab at Boston University, Darren Roblyer, PhD, studies mice, invents new medical devices, and guides a clinical trial for women getting chemotherapy as their first treatment for breast cancer. All 3 of these projects are funded by his grant from the American Cancer Society. They all also have the same goal: To learn how well chemotherapy is working to destroy a tumor, as quickly as possible after the treatment is started.

The American College of Surgeons National Surgical Quality Improvement Program has recognized the Mayo Clinic Hospitals in Rochester and Arizona for achieving meritorious outcomes for surgical patient care.  As a program participant, Mayo tracks the outcomes of inpatient and outpatient surgical procedures in order to inform and direct quality improvement efforts.

Mayo Clinic will have the first clinical 7-Tesla MRI scanner in North America that has been cleared by the U.S. Food and Drug Administration (FDA). This MRI scanner, the MAGNETOM Terra, will be operational at Mayo Clinic later in 2017. The manufacturer, Siemens Healthineers, received FDA clearance on October 12 for clinical use of the scanner to image the head and knee.

In the first study of its kind, an international team of genomics researchers has identified new regions of the human genome that are associated with skin color variation in some African populations, opening new avenues for research on skin diseases and cancer in all populations. These findings may help researchers determine if humans with certain DNA sequences are more or less susceptible to DNA damage caused by ultraviolet radiation (UVR) or respond to cellular stress differently. National Institutes of Health researchers contributed to this effort, led by Sarah Tishkoff, Ph.D., at the University of Pennsylvania in Philadelphia. The findings were published October 12, 2017, in the journal Science.

Results from a large randomized, placebo-controlled clinical trial in Liberia show that two candidate Ebola vaccines pose no major safety concerns and can elicit immune responses by one month after initial vaccination that last for at least one year. The findings, published in the October 12 issue of the New England Journal of Medicine, are based on a study of 1,500 adults that began during the West Africa Ebola outbreak. The trial is being conducted by a U.S.-Liberia clinical research collaboration known as the Partnership for Research on Ebola Virus in Liberia (PREVAIL), established in 2014 in response to the request from the Liberian Minister of Health to the U.S. Secretary of Health and Human Services.

To improve quality and reduce health care spending at a population level, state and federal agencies have begun requiring shared decision making tools for certain procedures and tests. With legal and financial incentives, the Centers for Medicare and Medicaid Services and others aim to move the industry toward value-based care.